Following regulatory attempts in Europe to revoke approval of its ANCA-associated vasculitis (AAV) therapy Tavneos (avacopan), developer Inflarx is now looking to advance two new treatments — both being tested in clinical trials — for this group of autoimmune diseases. The biopharmaceutical company said in a…
Discussion
A committee of the European Medicines Agency has recommended revoking the marketing authorization for Tavneos (avacopan) — an approved oral therapy for ANCA-associated vasculitis (AAV) — in the European Union (EU) over questions about the drug’s effectiveness data. The recommendation, from the Committee for Medicinal Products for…
Discussion
Our sweet cat, Sammie Cooper, died suddenly a few weeks ago. So this is a sad column, but it’s also an ode to a particular kind of care partner: the kind with fur. She came to us 13 years ago from a shelter in Tucson, Arizona. We figured she was…
Becoming educated and informed about ANCA vasculitis is a good first step. Here you’ll find general information such as the diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your ANCA vasculitis journey.
There is no cure for ANCA vasculitis yet, but here you can find more information about current approved treatments, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
